EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Beijing Winsunny Pharmaceutical CO.LTD (601089) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Beijing Winsunny Pharmaceutical CO.LTD ¥10.76, price ¥16.29, upside -34.0%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CN · ISIN CNE100005QF9

BW Broad data Sep 23, 2026

Beijing Winsunny Pharmaceutical CO.LTD

601089 · SHG

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value ¥10.76 · Overvalued (−34%)
!Quality 59/100
!Expensive Growth (revenue 5y +6.7 %/yr)
✓Solidly profitable · 12.5% net margin (TTM)
!Low debt · negative free cash flow
·3.07% dividend yield
✓Ranks above peers (8/13)
!Moderate moat 52/100
Watch Beijing Winsunny Pharmaceutical CO.LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥31.02 ¥11.26 Fair Value ¥10.76 Jun 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

51‑month range ¥11.26 – ¥31.02 · fair‑value band ¥7.36 – ¥16.17 · the ¥16.29 price screens above the ¥10.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Beijing Winsunny Pharmaceutical CO.LTD in your weekly email

Every Wednesday you see whether Beijing Winsunny Pharmaceutical CO.LTD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China.

Show more

Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China. The company offers chemical drugs; traditional Chinese medicine; raw materials; and medical devices, such as negative pressure drainage device, digital urine collection bags, dynamic urine output monitor, disposable pressure sensor, urodynamic monitoring device, nasal air filter, medical micro-mesh nebulizer, disposable atomizer, disposable oxygen mask, and disposable oxygen tubing. It sells its products through medical institutions and retail outlets. The company's products cover cardiovascular system, chronic kidney disease, dermatology, digestive system, diabetes, neuropsychiatric system, and gynecology areas. Beijing Foyou Pharma CO.,LTD was incorporated in 1999 and is headquartered in Beijing, China.

Stock analysis

Beijing Winsunny Pharmaceutical CO.LTD (601089) currently trades at ¥16.29, while our model-based Fair Value estimate is ¥10.76, implying the stock looks roughly 51.4% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ¥17.52 per share, and 6 of the 16 models we run sit above the ¥16.29 price.

Bear case: the Asset-Based group reads lowest at ¥5.28, and 10 of the 16 models stay below the price. Evidence for this calculation is high.

Scenario range: ¥7.36 (bear) to ¥16.17 (bull), the price of ¥16.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Beijing Winsunny Pharmaceutical CO.LTD reported revenue of 3.5B CNY in FY2025 versus 2.8B CNY in FY2021, a compound +5.4%/yr. Reported net income was 469M CNY in FY2025, compounding +10.5%/yr from FY2021.

Key figures

Market cap 8.5B CNY (≈ $1.3B) · P/E ratio 17.5 · P/S ratio 2.35 · EPS (TTM) ¥0.9300 · Dividend yield 3.1% · Net margin 13.4% · Return on equity 11.5% · Return on assets (EBIT) 12.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −34%, 601089 screens richer than that median.

Fair Value models

Bear ¥7.36 Fair Value ¥10.76 Bull ¥16.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.3145 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings ¥5.59 ¥7.41 ¥9.92 77
Residual Income ¥7.28 ¥8.50 ¥15.12 73
ROIC Compounder ¥9.31 ¥11.06 ¥13.03 72
All 16 models by family
DCF Models
Owner Earnings ¥5.59 ¥7.41 ¥9.92 77
Earnings-Based
Graham-Dodd ¥6.65 ¥16.04 ¥20.72 65
PEG = 1.0 ¥2.83 ¥4.05 ¥5.26 57
EPV ¥9.13 ¥10.37 ¥11.44 71
Dividend Discount
Gordon GGM ¥4.29 ¥7.41 ¥11.14 67
DDM Multi-Stage ¥4.29 ¥6.30 ¥8.42 67
Multiples
P/E Multiple ¥16.13 ¥21.51 ¥26.89 63
P/S Multiple ¥12.47 ¥16.62 ¥20.78 58
P/B Multiple ¥12.47 ¥16.62 ¥20.78 55
EV/EBIT ¥15.21 ¥19.84 ¥24.48 66
EV/EBITDA ¥15.57 ¥20.33 ¥25.09 67
EV/Revenue ¥11.22 ¥15.48 ¥19.73 54
Asset-Based
NCAV (Graham) ¥3.94 ¥5.28 ¥7.87 54
Economic Profit
Residual Income ¥7.28 ¥8.50 ¥15.12 73
ROIC Compounder ¥9.31 ¥11.06 ¥13.03 72
Growth Earnings
Growth-Adj P/E ¥12.26 ¥17.52 ¥22.78 67

Open the full fair value analysis →

Notify me when 601089 reaches fair value

Put 601089 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 58 · Market factors (momentum, volatility) 32

Profitability 61
Margins and returns on capital today
Quality Growth 37
Are margins and returns improving?
Cashflow 19
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 65
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+7.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.1%
Dividend (yield on the price)3.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 15%

601089 screens 51% overvalued. Compare with Merck KGaA →

Compare Beijing Winsunny Pharmaceutical CO.LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 611 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −34% · Below median
Profitability
Return on equity (TTM) 12% · Above median
Return on assets 6% · Above median
Net margin (TTM) 12% · Above median
Operating margin (TTM) 12% · Above median
Growth and dividend
Revenue growth −2% · Below median
Dividend yield (TTM) 3.1% · Above median
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 17.5× · Cheaper than median
P/B 2.25× · Pricier than median
P/S (TTM) 2.44× · Pricier than median
EV/EBITDA 13.7× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 12
FUTURE (revenue growth)0 · sector 20
PAST (return on equity)46 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)61 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.72 ¥50.29 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,846 ₹1,979 +7%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Winsunny Pharmaceutical CO.LTD · Fair Value
¥10.76 −51%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Beijing Winsunny Pharmaceutical CO.LTD Fair Value". https://www.fairvalue-calculator.com/stock/601089

Frequently asked questions

Is Beijing Winsunny Pharmaceutical CO.LTD (601089) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥10.76 versus a price of ¥16.29, about −34% upside (overvalued).
What is the fair value of 601089?
Our model-based fair value for Beijing Winsunny Pharmaceutical CO.LTD is ¥10.76 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥16.29.
What is the quality score of 601089?
Beijing Winsunny Pharmaceutical CO.LTD has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Our model-based price target is the fair value of ¥10.76 (as of Sep 23, 2026) from 16 valuation models. Cautious scenario ¥7.36, optimistic scenario ¥16.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Winsunny Pharmaceutical CO.LTD stock forecast for 2026?
Our models put fair value at ¥10.76, about −34% upside versus a price of ¥16.29 (overvalued). Cautious scenario ¥7.36, optimistic scenario ¥16.17. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Beijing Winsunny Pharmaceutical CO.LTD reported trailing-twelve-month revenue of about 3.5B CNY (latest available figure, as of Sep 23, 2026).
Does Beijing Winsunny Pharmaceutical CO.LTD pay a dividend?
Beijing Winsunny Pharmaceutical CO.LTD currently shows a dividend yield of about 3.07% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Winsunny Pharmaceutical CO.LTD it is ¥10.76 per share (as of Sep 23, 2026), against a price of ¥16.29. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Beijing Winsunny Pharmaceutical CO.LTD stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 601089 trades above its calculated fair value: price ¥16.29, fair value ¥10.76, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 601089?
No. The price is what the market pays today (¥16.29); the fair value is what the company's own numbers justify (¥10.76). For Beijing Winsunny Pharmaceutical CO.LTD the two are ¥5.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Winsunny Pharmaceutical CO.LTD worth?
The market values Beijing Winsunny Pharmaceutical CO.LTD at about 8.5B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥16.29; our models calculate a fair value of ¥10.76 per share.
What do the bullish and bearish scenarios say about 601089?
Our models span a range for Beijing Winsunny Pharmaceutical CO.LTD: cautious scenario ¥7.36, base ¥10.76, optimistic ¥16.17 per share (as of Sep 23, 2026, price ¥16.29). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 601089?
Beijing Winsunny Pharmaceutical CO.LTD trades at a price-to-earnings ratio of 17.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥10.76 is built from several models across several years. Other multiples: P/B 2.3, P/S 2.4, EV/EBITDA 13.7.
How solid is the balance sheet of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Balance-sheet figures for Beijing Winsunny Pharmaceutical CO.LTD (as of Sep 23, 2026): return on equity 11.5%, debt of 0.00 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 601089 from its 52-week high?
Beijing Winsunny Pharmaceutical CO.LTD trades at ¥16.29, about 45% below its 52-week high of ¥29.45 and 5% above the low of ¥15.46 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.76 is for.
Which stocks are comparable to Beijing Winsunny Pharmaceutical CO.LTD?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Winsunny Pharmaceutical CO.LTD stock attractive at the current price?
The data as of Sep 23, 2026: price ¥16.29, calculated fair value ¥10.76 (−34%), Quality Score 59/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 601089 calculated?
We run Beijing Winsunny Pharmaceutical CO.LTD through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥10.76, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Beijing Winsunny Pharmaceutical CO.LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The closing price on Sep 23, 2026 was ¥16.29. Our model-based fair value is ¥10.76, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Winsunny Pharmaceutical CO.LTD right now?
Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥7.36 to ¥16.17) leaves room in how you read the outcome.

Key figures of Beijing Winsunny Pharmaceutical CO.LTD

How large is the market capitalisation of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The market capitalisation of Beijing Winsunny Pharmaceutical CO.LTD is 8.5B CNY (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The price-to-sales ratio of Beijing Winsunny Pharmaceutical CO.LTD is 2.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Earnings per share at Beijing Winsunny Pharmaceutical CO.LTD are ¥0.9300 (price ÷ EPS = P/E 17.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The dividend yield of Beijing Winsunny Pharmaceutical CO.LTD is 3.1% (payout 53.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The net margin of Beijing Winsunny Pharmaceutical CO.LTD is 13.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The return on equity (ROE) of Beijing Winsunny Pharmaceutical CO.LTD is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
On an EBIT basis the return on assets of Beijing Winsunny Pharmaceutical CO.LTD is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The operating margin of Beijing Winsunny Pharmaceutical CO.LTD is 12.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Revenue at Beijing Winsunny Pharmaceutical CO.LTD is growing −2.3% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Earnings per share at Beijing Winsunny Pharmaceutical CO.LTD are growing −25.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Winsunny Pharmaceutical CO.LTD (601089) generate?
The free cash flow of Beijing Winsunny Pharmaceutical CO.LTD is −36.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Beijing Winsunny Pharmaceutical CO.LTD in the live analysis

One click puts Beijing Winsunny Pharmaceutical CO.LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.